SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid a steep selloff, with traders pointing to scheduled lockup expirations and potential insider-share supply, alongside concerns about its IPO valuation, growth and ability to scale. The debate pits bearish calls for further declines against dip-buyers who remain bullish on Cerebras AI-inference technology and long-term demand.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided quarterly results and upbeat 2027 EBITDA outlook have driven a sharp rally, with traders debating whether short covering could extend the move. Bulls see improving steel operations and prices, while skeptics question whether the outlook can overcome the companys debt and reliance on favorable steel markets; some also warn the rally could fade.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as traders focus on financing costs, debt concerns and doubts about the sectors business models, with CoreWeaves credit worries adding to contagion fears. The community is split on whether sharp rebounds are durable or bull traps: bulls point to Nebiuss comparatively stronger balance sheet and long-term compute demand, while bears question the capital intensity and path to profitability.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound conversation after a steep selloff, but traders remain focused on CoreWeaves debt burden, financing costs and ability to turn AI demand and its backlog into cash flow. Bulls call the selloff overdone and welcome the upgrade, while skeptics argue it does not resolve the financing risks and question whether the bounce will hold.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus pancreatic cancer IMPACT trial completed enrollment after expanding from 12 to 48 patients, which traders view as a sign of strong clinical-site and patient interest; the results are still pending. Attention also centers on the FDA-cleared expansion of its recurrent glioblastoma REGAIN trial and anticipated clinical updates, with mostly bullish reactions tempered by uncertainty about what the larger studies will show.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp pullback despite strong operating results is fueling debate, with traders frequently blaming insider share sales and managements failure to announce a fresh buyback; some also cite an analyst downgrade and regional macro concerns. Bears see continued weakness, while bulls argue the selloff has made the growing e-commerce and fintech business more attractive.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XEs steep selloff and search for a bottom dominate the discussion, with traders attributing pressure to post-IPO selling, bearish analyst coverage, and weakness across nuclear stocks. Some see Amazons backing and potential SMR demand from data centers as a long-term positive, while others remain concerned that commercialization is years away.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

FDA expanded ANKTIVA plus BCG to cover papillary-only BCG-unresponsive bladder cancer, broadening its potential market; traders also focused on long-term Phase 3 data showing durable responses and bladder-sparing outcomes. Despite bullish views on the commercial opportunity, the shares sold off, with the community debating a sell-the-news reaction and broader biotech weakness versus options-related or short-selling pressure, while some remain cautious about revenue growth and dilution.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are focused on Disneys recent rebound and repeated tests of resistance, debating whether it can break out or will keep slipping back into its trading range. Bullish posts point to buyers defending the pullback, while bearish traders cite failed attempts to hold gains and downside options activity.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is drawing attention ahead of its Q3 earnings report as shares retreat amid a broader tech and AI selloff. Traders are split over whether strong ad performance and Muse AI momentum can justify heavy AI spending, with capex and returns on that investment central to expectations for the report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV

(RTTNews) - Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses...

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV ProgramPR NewswireCAMBRIDGE, Mass., Sept. 29, 2026 Once-Weekly Intranasal Potential...

Catalysts Keeping Momentum Going

Today’s tape is driven by catalysts; from a proposed balance-sheet reset at Beneficient (NASDAQ:BENF) to others for Wheeler REIT (NASDAQ:WHLR), Decoy Therapeutics (NASDAQ:DCOY), Greenland Mines Ltd. (NASDAQ:GRML), NeOnc Technologies Holdings (NASDAQ:NTHI), Professional Diversity Network (NASDAQ:IPDN), and Maison Solutions (NASDAQ:MSS).

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleasePR NewswireHOUSTON, Sept. 22, 2026 HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY)(the...

Stocks Riding Compelling Catalysts

Among the listings positioned for strong sessions are Rain Enhancement Technologies (NASDAQ:RAIN), Butterfly Network (NYSE:BFLY), NeOnc Technologies Holdings (NASDAQ:NTHI), Surgery Partners (NASDAQ:SGRY), Omeros (NASDAQ:OMER), Ginkgo Bioworks (NYSE:DNA), and bioAffinity (NASDAQ:BIAF). Meanwhile, Decoy Therapeutics (NASDAQ:DCOY), Filana Therapeutics (NASDAQ:FLNA), Jaguar Health (NASDAQ:JAGX), Maze Therapeutics (NASDAQ:MAZE), Viking Therapeutics (NASDAQ:VKTX), Greenland Mines (NASDAQ:GRML), and Lianhe Sowell International (NASDAQ:LHSW) remain squarely on the market's high-catalyst radar.

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq RulesPR...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million.
Greenland Mines (NASDAQ:GRML) shares rose 39.21% toread more...

Ebola Surprise Puts Decoy’s AI Antiviral Platform on a Much Bigger Stage

Decoy Therapeutics (NASDAQ:DCOY) is suddenly talking about viruses far beyond the respiratory diseases at the center of its original development strategy, as an unexpected laboratory result could open an entirely new biodefense opportunity.

Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive FundingPR NewswireCAMBRIDGE, Mass., Sept. 22, 2026 Next-Generation D-MAVs Demonstrate Potent In...

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform PR Newswire CAMBRIDGE, Mass., Aug. 3, 2026 Portfolio now...

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

Decoy Therapeutics Inc.

DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The company has received $3.5 million from an unnamed institutional investor through a private placement.</li><li>Additional funding can be secured from the investor if certain milestones are achieved.</li><li>Decoy is currently working on a nasal-based therapy that can cure all kinds of coronaviruses and a “tripledemic” vaccine that can protect against flu, coronaviruses, and respiratory syncytial viruses.</li></ul><p>Shares of Decoy Therapeutics (DCOY) soared on Monday after the company secured up to $21 million to fund clinical trials of its lead programs targeting respiratory viral illnesses.</p><p>At the time of writing, DCOY stock was up more than 84%.</p><h2 class="st-heading-2"><strong>DCOY Secures Milestone-Based Funding</strong></h2><p>According to an SEC filing, the company has secured funding from an unnamed institutional investor through a private placement offering, under which Decoy sold 592,217 shares at $5.97 per share, raising $3.5 million.</p><p>The investor was also issued milestone-based Series A, Series B, and Series C common warrants, exercisable upon the company's achievement of certain targets. Proceeds from warrant redemptions would be an additional $17.5 million.</p><h2 class="st-heading-2"><strong>What Milestones Is DCOY Targeting?</strong></h2><p>The company will be able to receive an additional $3.5 million in funding from Series A warrants, when exercised, once it applies to begin Phase 1 trials in Europe. It will receive $7 million from Series B warrants once the U.K. health regulator greenlights its Phase 2a human challenge trial, and another $7 million from Series C warrants if the early-stage U.K. trial is successful.</p><p>According to the company, it is focused on Designable Multi-Antivirals (D-MAVs), which aim to enable a single drug to work against multiple viral threats, to evolve from the traditional one-virus, one-drug model.</p><p>Decoy is currently working on a nasal-based therapy that can cure all kinds of coronaviruses and a “tripledemic” vaccine that can protect against flu, coronaviruses, and respiratory syncytial viruses.</p><h2 class="st-heading-2"><strong>What Do Retail Traders Think About DCOY?</strong></h2><p>On Stocktwits, retail sentiment on DCOY turned ‘extremely bullish’ from ‘neutral’ over the last 24 hours.</p><p><a href="https://stocktwits.com/symbol/DCOY">DCOY stock</a> has declined more than 29% so far this year and more than 91% over the last 12 months, underperforming the S&amp;P 500.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background. (Source: Getty Images)

Shares of Decoy Therapeutics (DCOY) soared on Monday after the company secured up to $21 million to fund clinical trials of its lead programs targeting respiratory viral illnesses.

Decoy Therapeutics has secured funding to begin clinical trials for its programs targeting respiratory illnesses.


Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.17
Prev Close	$1.17
Open	$1.19
Dividend Yield	0.00%
50-Day Moving Average	$2.67
Beta	0.22
Avg. Volume	6.47M
PE Ratio	-0.02

52-Week High	$50.60
52-Week Low	$1.15
Market Capitalization	$2.79M
EPS (Annual)	-$129.10
Price to Book	0.14
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

DCOY Fundamentals